Cytochrome P450 2D6 genotype and methadone steady-state concentrations.
A genetic polymorphism of cytochrome P450 2D6 has been described with the existence of poor (zero functional genes), extensive (one or two functional genes), and ultrarapid metabolizers (three or more functional genes). The authors measured the steady-state trough (R)- (i.e., the active enantiomer), (S)-, and (R,S)-methadone plasma levels in opiate-dependent patients receiving methadone maintenance treatment (MMT) and genotyped them for cytochrome P4502D6. The patients' medical records were reviewed to assess the outcome of the MMT with regard to the absence of illicit opiate consumption and to the absence of withdrawal complaints in ultrarapid and poor metabolizers. Of 256 patients included, 18 were found to be poor metabolizers, 228 to be extensive metabolizers, and 10 to be ultrarapid metabolizers. Significant differences were found between genotypes for (R)- (p = 0.024), (S)- (p = 0.033), and (R,S)-methadone (p = 0.026) concentrations to dose-to-weight ratios. For (R)-methadone, a significant difference was found between ultrarapid metabolizers and poor metabolizers (p = 0.009), with the median value in the former group being only 54% of the median value in the latter group. These results confirm the involvement of cytochrome P450 2D6 in methadone metabolism. Although the difference was nonsignificant (p = 0.103), 13 (72%) of the 18 poor metabolizers and only 4 (40%) of the 10 ultrarapid metabolizers were considered successful in their treatment. More studies are needed to examine the influence of the ultrarapid metabolizer status on the outcome of the MMT.
Département Universitaire de Psychiatrie Adulte, H pital de Cery, Prilly-Lausanne, Switzerland. Chin.Eap@inst.hospvd.ch
C B
CB
Eap
F
F
Broly
A
A
Mino
R
R
Hämmig
J J
JJ
Déglon
C
C
Uehlinger
D
D
Meili
A F
AF
Chevalley
G
G
Bertschy
D
D
Zullino
M
M
Kosel
M
M
Preisig
P
P
Baumann
D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D016001:Confidence Intervals; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics* / Q000502:physiology; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008691:Methadone / Q000097:blood* / Q000627:therapeutic use; D008875:Middle Aged; D009294:Narcotics / Q000097:blood* / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*; D018709:Statistics, Nonparametric
D009294:Narcotics; D019389:Cytochrome P-450 CYP2D6; D008691:Methadone